Voyager Therapeutics' (VYGR) Buy Rating Reaffirmed at HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $30.00 price objective on the stock.

VYGR has been the subject of several other research reports. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research note on Friday, January 10th. They issued an "overweight" rating and a $5.73 price target for the company. StockNews.com cut Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Citigroup began coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a "buy" rating and a $12.00 target price on the stock. Wedbush reissued an "outperform" rating and issued a $9.00 price target (down previously from $11.00) on shares of Voyager Therapeutics in a report on Tuesday, February 11th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Voyager Therapeutics has an average rating of "Buy" and a consensus target price of $15.72.

Voyager Therapeutics Price Performance

VYGR stock traded down $0.17 during midday trading on Monday, hitting $3.91. 383,912 shares of the stock traded hands, compared to its average volume of 362,550. Voyager Therapeutics has a 1-year low of $3.88 and a 1-year high of $10.66. The stock's fifty day simple moving average is $5.18 and its 200-day simple moving average is $6.00. The firm has a market cap of $213.59 million, a P/E ratio of 5.51 and a beta of 0.91.

Insider Activity

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 10,778 shares of company stock valued at $58,548 in the last 90 days. Company insiders own 4.53% of the company's stock.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VYGR. Cubist Systematic Strategies LLC purchased a new position in Voyager Therapeutics during the fourth quarter worth about $29,000. Tower Research Capital LLC TRC raised its stake in shares of Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock valued at $31,000 after acquiring an additional 3,077 shares during the period. Picton Mahoney Asset Management lifted its holdings in shares of Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after acquiring an additional 2,444 shares during the last quarter. Oxford Asset Management LLP purchased a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $60,000. Finally, Intech Investment Management LLC acquired a new stake in Voyager Therapeutics in the 3rd quarter valued at approximately $74,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.